Richard W. Lowry, M.D., F.A.C.C.

1983-1987: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma. Doctor of Medicine,1987
1979-1983: Stanford University, Palo Alto, California, Bachelor of Arts in Human Biology, 1983

Post-Graduate Training

7/1987-6/1988: Internship in Medicine, Charity Hospital, Veterans Administration Hospital and Tulane Medical Center, New Orleans, Louisiana
7/1988-6/1990: Residency in Medicine, Charity Hospital, Veterans Administration Hospital and Tulane Medical Center, New Orleans, Louisiana
7/1990-6/1994: Fellowship in Cardiology, Baylor College of Medicine Affiliated, Hospitals, Houston, Texas
7/1993-6/1993: Fellowship in Interventional Cardiology, Baylor College of Medicine, Affiliated Hospitals, Houston, Texas

Licensure

1990, 2006: State of Texas #H8733
1987: State of Louisiana #07638R
1994: State of Oklahoma #19408 (7/01/1994)

Board Certification

2006: International Board of Hearth Rhythm Examiners, Formerly NASPExam #1172
1999: American Board of Internal Medicine, Subspecialty Board of Interventional Cardiology #134899
1990: American Board of Internal Medicine, September 12, 1990 #134899
1993,2003: American Board of Internal Medicine, Subspecialty Board of Cardiovascular Disease #134899

Hospital Appointments

2006-Present: Trinity Mother Frances Hospital - Tyler, Texas
2006-Present: East Texas Medical Center - Tyler, Texas
2006-Present: East Texas Medical Center - Athens, Texas
2007-Present: East Texas Medical Center - Quitman, Texas

Memberships

American Medical Association
Fellow of American College of Cardiology – 1995
Fellow of The Society for Cardiac Angiography & Interventions, 2001

Professional Activities

1999-Present: Editorial Consultant, The Society for Cardiac Angiography & Interventions
1997-Present: Medical Advisory Board, Scimed

Research

Primary Investigator - PLATO Study - A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).
Co Investigator – LEAP -- A Two Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Simvastatin, Losartan, and Pioglitazone on Cardiovascular disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Artery Disease.
Co-Investigator – RE-LY - Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.
Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.
BEST – Beta-blocker evaluation of survival trial. Mortality study to evaluate Bucindolol versus placebo in patients with Class III/IV CHF and EF < 35%. (NHLBI & VA Cooperative Studies Program)
PRAISE-2 - Prospective Randomized Amlodipine Survival Evaluation-2. To evaluate the effect of amlodipine on survival in patients with congestive heart failure (non-ischemic etiology) and EF < 30%. No beta blocker allowed. (Pfizer, Inc.)
Val-Heft - Valsartan in heart failure. Placebo controlled study to evaluate the effect of Valsartan on morbidity and mortality, signs and symptoms and quality of life in patients with stable, chronic CHF (NYHA Class II-IV). EF < 40%. May be on beta blocker. (Novartis)
SCD-HeFT – Sudden cardiac death in heart failure trial. Amiodarone vs. an implantable cardioverter – defibrillator (ICD) vs. placebo (I:I:I) in the treatment of patients with NYHA II/III CHF. EF< 35%. (NHLBI)
RENAISSANCE – Multi-center, double-blind, randomized, placebo-controlled, Phase II/III study of the effect of recombinant human tumor necrosis factor receptor Fe fusion protein (TNFR:Fe)(etanercept) on clinical improvement in patients with chronic heart failure.
SPORT – Stent implantation post rotational atherectomy trial.
ULTRA – ULTRA-GX 2.5 acute or threatened closure registry.
MOXCON – The effect of sustained release moxonidine on mortality and morbidity in patients with congestive heart failure.
ATP – The effect of LDL-cholesterol lowering beyond currently recommended minimum targets on coronary heart disease (CHD) recurrence in patients with pre-existing CHD.
MUSTT- Multi-centered unsustained tachycardia trial.
OPUS/TIMI 16 – Phase III international randomized double-blind placebo-controlled trial evaluating the efficacy and safety of Orbofiban in patients with unstable coronary syndromes.
TcN-NOET - Cardiac imaging agent.
Wallstent Study – WIN – Wallstent in native coronary arteries. Nonrandomized – all patients who qualify get Wallstent. WINS – Wallstent in SV-CABG vessels. Randomized to Wallstent or J&J stent (1:1). (Schneider)
In Time-II – Double-blind, randomized, multicenter trial of single-bolus Lanoteplase versus accelerated alteplase for the treatment of subjects with acute myocardial infarction. Randomized 2:1, chest pain x 30 minutes within 6 hours. (Bristol-Myers Squibb).
SADHART – A randomized double-blind, placebo-controlled trial of sertraline (Zoloft) for major depression after myocardial infarction. MI within 30 days. (Pfizer and Duke).
GEM DR – Evaluation of patients implanted with an implantable cardioverter defibrillator combined with a dual chamber rate responsive pacemaker. Inclusion criteria: one episode of sudden cardiac death or recurrent poorly tolerated sustained VT. (Medtronic)
Destini-FloWire Registry – Any patient who undergoes evaluation with a FloWire should be entered in this registry. (Cardiometrics).